P
0.912
0.01 (1.52%)
| Previous Close | 0.899 |
| Open | 0.903 |
| Volume | 319,686 |
| Avg. Volume (3M) | 417,793 |
| Market Cap | 56,497,540 |
| Price / Book | 0.470 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2026 |
| Diluted EPS (TTM) | -3.61 |
| Total Debt/Equity (MRQ) | 23.40% |
| Current Ratio (MRQ) | 11.03 |
| Operating Cash Flow (TTM) | -174.10 M |
| Levered Free Cash Flow (TTM) | -112.84 M |
| Return on Assets (TTM) | -33.89% |
| Return on Equity (TTM) | -63.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Pliant Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.24 |
Select this tab to load the latest available analysis.
|
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.04% |
| % Held by Institutions | 95.97% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |